Despite progress made over the past 25 years, existing immunotherapies have limited
clinical effectiveness in patients with cancer. Immune tolerance consistently blunts the
generated immune response, and the largely solitary focus on CD8+ T cell immunity has
proven ineffective in the absence of CD4+ T cell help. To address these twin-tier
deficiencies, we developed a translational model of melanoma immunotherapy focused on
the exploitation of high-avidity CD4+ T cells that become generated in germline antigen …